Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma-Reference-Cited by-同舟云学术

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma

Published:2019-04-16 Issue:1 Volume:19 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Zhang Xingming,Yin Xiaoxue,Zhang Haoran,Sun Guangxi,Yang Yaojing,Chen Junru,Zhu Xudong,Zhao Peng,Zhao Jinge,Liu Jiandong,Chen Ni,Wang Jia,Shen Pengfei,Zeng Hao^ORCID

Funder

Natural Science Foundation of China

Science and Technology Support Program of Sichuan Province

1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-019-5578-4.pdf

Reference43 articles.

1. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183(2):131–3.

2. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32.

3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843–52.

4. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96.

5. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of modern immunotherapy in combination treatment of patients with renal cancer and bone metastases;Cancer Urology;2024-08-15

2. Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review);International Journal of Oncology;2024-02-13

3. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC;Liver International;2024-01-30

4. A model for predicting clinical prognosis based on brain metastasis-related genes in patients with breast cancer;Translational Cancer Research;2023-12

5. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases;Journal for ImmunoTherapy of Cancer;2023-08